Radius Health, Inc. (NASDAQ:RDUS) Receives $8.60 Consensus Target Price from Analysts

Radius Health, Inc. (NASDAQ:RDUSGet Rating) has received a consensus recommendation of “Hold” from the six brokerages that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $8.60.

A number of research analysts have recently weighed in on RDUS shares. The Goldman Sachs Group cut their price objective on Radius Health from $9.00 to $8.00 and set a “neutral” rating on the stock in a report on Tuesday, May 24th. SVB Leerink raised their price objective on Radius Health from $7.00 to $10.00 and gave the company a “market perform” rating in a report on Friday, June 24th. StockNews.com started coverage on Radius Health in a research report on Sunday. They issued a “buy” rating on the stock. Finally, Bank of America upgraded Radius Health from an “underperform” rating to a “neutral” rating and set a $8.00 price objective on the stock in a research report on Wednesday, June 8th.

Radius Health Price Performance

Shares of NASDAQ RDUS opened at $10.08 on Friday. The stock has a market capitalization of $480.01 million, a P/E ratio of -6.90 and a beta of 0.51. Radius Health has a 1-year low of $4.97 and a 1-year high of $23.00. The business has a fifty day moving average price of $10.09 and a 200 day moving average price of $8.67.

Radius Health (NASDAQ:RDUSGet Rating) last issued its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.35). The company had revenue of $58.29 million during the quarter, compared to analysts’ expectations of $67.95 million. As a group, equities research analysts anticipate that Radius Health will post -0.18 earnings per share for the current fiscal year.

Insider Activity at Radius Health

In other news, major shareholder Rubric Capital Management Lp acquired 4,012 shares of the firm’s stock in a transaction dated Wednesday, August 10th. The stock was acquired at an average cost of $10.07 per share, with a total value of $40,400.84. Following the completion of the acquisition, the insider now owns 6,963,317 shares of the company’s stock, valued at $70,120,602.19. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. 1.73% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Point72 Hong Kong Ltd acquired a new stake in shares of Radius Health during the fourth quarter valued at $45,000. Amalgamated Bank purchased a new position in shares of Radius Health in the 1st quarter worth about $68,000. Lazard Asset Management LLC raised its holdings in shares of Radius Health by 507.1% in the 2nd quarter. Lazard Asset Management LLC now owns 7,231 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 6,040 shares during the period. Douglas Lane & Associates LLC purchased a new stake in shares of Radius Health during the 1st quarter valued at about $88,000. Finally, XTX Topco Ltd purchased a new stake in shares of Radius Health during the 1st quarter valued at about $90,000.

About Radius Health

(Get Rating)

Radius Health, Inc, a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome.

See Also

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.